Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
The concept of contract research organizations is on the rise. Wuxi AppTec (02359) rose by 4.97%. Institutions predict that the performance of the pharmaceutical sector will show a marginal improvement trend.
Jingu Finance News | The concept of contract research organizations is up across the board. As of press time, Genscript Bio (01548) rose 6.07%, Wuxi AppTec (02359) rose 4.97%, Viva Biotech (01873) rose 4%, and Pharmaron (03759) rose 3.64%. On the news front, Xingye Securities issued a research report stating that the market attention to the pharmaceutical sector has gradually recovered recently. Looking back, the pharmaceutical sector experienced a downtrend of more than 2 months, with the CSI 300 Index down 11.0% (as of the close of August 2), while the Shanghai and Shenzhen 300 Index was also down 6.1% during the same period. Currently, the pharmaceutical sector is valued
Haitong Int'l: active investment and financing market, CRO companies accelerate layout of AI+pharmaceutical application technology.
With the continuous advancement of AI technology and the enhanced professional capabilities of CRO companies, it is expected that there will be more innovative breakthroughs in the field of drug research and development in the future.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
Contract research organizations are generally increasing. Pharmaron (03759) rose 6.66%, and Orient Securities is expected to see marginal improvement in the sector.
Jingu Financial News| The concept of contract research organizations is rising across the board. As of the time of publication, Pharmaron (03759) rose 6.66%, Viva Biotech (01873) rose 5.05%, Tigermed (03347) rose 2.84%, and Wuxi Bio (02269) rose 2.77%. On the news side, Orient Securities stated that according to the latest data on the key indicators of the CRO industry's prosperity index, the global fund has basically stabilized, while the domestic investment and financing side is still tight; however, the enthusiasm for research and development has not diminished, and the IND and new clinical trials are still at a high level. The bank believes that the CXO sector, after experiencing double killings in performance and valuation, is expected to welcome a
Trending Industry Today: FRONTAGE Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Viva Biotech Corrects Clerical Error in Key Document
Investors Give Viva Biotech Holdings (HKG:1873) Shares A 29% Hiding
Viva Biotech Announces Share Option Schemes
Via Biotech (01873): Via Shanghai has decided to adopt the first phase of the Via Shanghai equity incentive plan and the second phase of the Via Shanghai equity incentive plan
VIA Biotech (01873) issued an announcement. On May 31, 2024, VIA Shanghai shareholders have decided to adopt VIA...
Changes in Hong Kong stocks | CRO concept stocks picked up in early trading, and many companies began to adjust their business in the US. Institutions say industry demand is expected to recover in the second half of the year
CRO concept stocks picked up in early trading. As of press release, Viva Biotech (01873) rose 3.13% to HK$0.66; Kanglong Chemical (03759) rose 2.82% to HK$9.86; Pharmaceutical Biotech (02269) rose 2.68% to HK$11.5; and Pharmaceuticals (02359) rose 2.31% to HK$35.45.
Changes in Hong Kong stocks | CRO concept stocks continue to rebound, the downstream demand side needs to improve, and domestic CXO companies still have a competitive advantage
CRO concept stocks continued to rebound. As of press release, Viva Biotech (01873) rose 8.93% to HK$0.61; Kingsley Biotech (01548) rose 8.35% to HK$11.94; Kanglong Chemical (03759) rose 5.91% to HK$10.04; and Pharmaceutical Biotech (02269) rose 5.79% to HK$14.26.
VIVA BIOTECH: 2023 Annual Report
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 34% Share Price Slump
Viva Biotech (01873) announced annual results, losses attributable to shareholders of 116 million yuan narrowed by 78.03% year-on-year
Viva Biotech (01873) announced its annual results for the year ended December 31, 2023, with group revenue of RMB 21...
No Data